Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Ascending High-Dose, Add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs).

Trial Profile

A Phase II, Open-Label, Ascending High-Dose, Add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary) ; Antiepileptic drugs; Carbamazepine; Clobazam; Clonazepam; Gabapentin; Lamotrigine; Phenobarbital; Phenytoin; Topiramate; Valproate; Zonisamide
  • Indications Generalised seizures; Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd

Most Recent Events

  • 30 Nov 2016 According to an Eisai media release, the company will present results of this study at the 70th American Epilepsy Society (AES) Annual Meeting.
  • 19 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 15 Sep 2009 Actual initiation date changed from Feb 2009 to Mar 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top